Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21402629 | 0.87 | USP2 (0.36) | USP2MEN1KMT2A | |
| SCHEMBL21809426 | 0.81 | CYP1A2 (0.36) | CA1CA2CA4USP2KDM4E | |
| SCHEMBL20169128 | 0.76 | CYP19A1 (0.35) | CA1CA2CA4USP2KDM4E | |
| SCHEMBL29314984 | 0.75 | CA1 (0.48) | CA1CA2CA4 | |
| SCHEMBL21402656 | 0.75 | CA1 (0.46) | CA1CA2CA4MEN1KMT2A | |
| SCHEMBL21402642 | 0.73 | MEN1 (0.44) | USP2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL21402635 | 0.72 | MEN1 (0.36) | USP2KDM4EMEN1KMT2A | |
| SCHEMBL21402609 | 0.70 | KDM4E (0.33) | USP2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL21402621 | 0.70 | MEN1 (0.40) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL13745541 | 0.69 | CA1 (0.50) | CA1CA2CA4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225739-B | Wrinkle-improving agent | 宝丽化成工业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10813859-B2 | Wrinkle ameliorating agent | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3545942-A1 | WRINKLE AMELIORATING AGENT | Pola Chemical Industries Inc. (JP) | 2019-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813859-B2 | Wrinkle ameliorating agent | COL2A1, COL1A1, COL14A1 | CA1 4834/4885CA2 4081/4885CA4 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.